Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Curr Cardiol Rep. 2022 Sep;24(9):1169-1177. doi: 10.1007/s11886-022-01734-0. Epub 2022 Jul 7.
A polygenic risk score (PRS) is a measure of genetic liability to a disease and is typically normally distributed in a population. Individuals in the upper tail of this distribution often have relative risk equivalent to that of monogenic form of the disease. The majority of currently available PRSs for coronary heart disease (CHD) have been generated from cohorts of European ancestry (EUR) and vary in their applicability to other ancestry groups. In this report, we review the performance of PRSs for CHD across different ancestries and efforts to reduce variability in performance including novel population and statistical genetics approaches.
PRSs for CHD perform robustly in EUR populations but lag in performance in non-EUR groups, particularly individuals of African ancestry. Several large consortia have been established to enable genomic studies in diverse ancestry groups and develop methods to improve PRS performance in multi-ancestry contexts as well as admixed individuals. These include fine-mapping to ascertain causal variants, trans ancestry meta-analyses, and ancestry deconvolution in admixed individuals. PRSs are being used in the clinical setting but enthusiasm has been tempered by the variable performance in non-EUR ancestry groups. Increasing diversity in genomic association studies and continued innovation in methodological approaches are needed to improve PRS performance in non-EUR individuals for equitable implementation of genomic medicine.
多基因风险评分(PRS)是衡量疾病遗传易感性的一种方法,通常在人群中呈正态分布。分布曲线尾部的个体通常具有与单基因形式疾病相当的相对风险。目前大多数用于冠心病(CHD)的 PRS 都是从欧洲血统(EUR)的队列中生成的,其在其他血统群体中的适用性存在差异。在本报告中,我们综述了不同血统人群中 CHD 的 PRS 表现,以及降低表现变异性的努力,包括新的人群和统计遗传学方法。
CHD 的 PRS 在 EUR 人群中表现稳健,但在非 EUR 人群中表现滞后,尤其是非洲裔个体。已经建立了几个大型联盟,以在不同血统群体中开展基因组研究,并开发方法来提高多血统背景和混血个体中 PRS 的性能。这些方法包括精细映射以确定因果变异、跨血统荟萃分析以及混血个体中的血统去卷积。PRS 已在临床环境中使用,但由于非 EUR 血统群体中的表现存在差异,其应用受到了限制。需要增加基因组关联研究的多样性,并不断创新方法学方法,以提高非 EUR 个体中 PRS 的性能,从而实现基因组医学的公平实施。